الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 115 |  |  |
| | | from | 115 | | |
Abstract
Background: There is a significant upsurge of prostate cancer incidence around the world. As there are no current independent biomarkers with high diagnostic efficiency to detect prostate cancer, this study was performed to investigate the relative gene expression levels of E2F3 and survivin in the whole blood of prostate cancer (PC), benign prostate hyperplasia (BPH), and normal control individuals.
Methods: Participants of the study were divided into three groups; normal control group (n=25), BPH patients (n=25), and PC patients (n=75). The E2F3 and survivin gene expression levels were assessed using real-time qPCR in addition to the measurement of free and total levels of prostate-specific antigen (PSA) using electro-chemiluminescence assays. Additionaly, PSA ratio was calculated.
Results: Survivin relative gene expression was over-expressed in PC and BPH patients compared to the normal control group, whereas, E2F3 did not differ significantly among the studied groups. Compared to PSA, E2F3 and survivin expression levels have lower diagnostic efficacy in discriminating PC patients. Further, survivin expression level was associated with increased the risk of prostate cancer.
Conclusion: Survivin and E2F3 relative expression levels in peripheral blood had low diagnostic performance to detect prostate cancer and individuals with high survivin expression levels may have higher risk to develop prostate cancer.